4,901 trials
Healthy Volunteers · Hepatic Insufficiency · Diabetes Mellitus, Type 2
Primary: Pharmacokinetics: Area Under the Concentration Time Curve From Zero to Infinity (AUC[0-∞]) of LY2605541 — 85200; 67200; 64300; 66600 picomole*hours/liter (pmol*h/L)
Major Depressive Disorder
Primary: Pharmacokinetics: Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of S-Warfarin — 22200; 20800 nanogram*hour per milliliter (ng*hr/mL)
Dose Finding Study
Primary: Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event (TEAE) — 30.0; 55.6; 37.5; 14.3 percentage of participants
Major Depressive Disorder
Primary: Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration-Time Curve Over a 24-Hour Dosing Interval (AUCτ) of LY2216684 — 675; 792 hour*nanogram per milliliter…
Healthy Volunteers
Primary: Pharmacokinetics: Observed Maximum Concentration (Cmax) of Insulin Peglispro — 3720 picomoles/liter (pmol/L)
Depressive Disorder, Major
Primary: Pharmacokinetics: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-∞) of LY2216684 — 509; 786 nanogram*hour/milliliter (ng*h/mL)
Diabetes Mellitus, Type 2
Primary: Part B: Mean Change From Baseline in 12-lead Electrocardiogram (ECG) Corrected QT Intervals (LY2409021) — -14.72; -15.35; -5.43; -9.12 milliseconds
Advanced Metastatic Breast Cancer
Primary: Adverse Events — 6; 13; 14; 10 Participants
Metastatic Renal Cell Cancer
Primary: Recommended Dose for Phase 2 Studies of LY573636-Sodium Combined With Sunitinib in Participants With Metastatic Renal Cell Carcinoma — NA; NA; NA; NA micrograms per…
Type 2 Diabetes Mellitus
Primary: Number of Participants With All-Causality and Treatment Related Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events — 5; 3; 3; 5 participants
Acute Myeloid Leukemia · Essential Thrombocythemia
Primary: Recommended Phase 2 Dose of LY573636-Sodium in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Essential Thrombocythemia (ET)
Intravitreal Bevacizumab Injection · Pars Plana Vitrectomy · Tractional Retinal Detachment
Primary: Best Corrected Visual Acuity — 1.1; 1.4 LogMar
Healthy Volunteers
Primary: Pharmacokinetics: Area Under the Concentration-Time Curve (AUC): Injection Site (Arm and Thigh) Versus Abdominal Wall Injection (Cohort A) — 124000; 133000; 135000…
Solid Tumors
Primary: Recommended Phase 2 Dose — NA; NA; NA; NA micrograms per milliliter (μg/mL)
Solid Tumor · Pancreatic Cancer
Primary: Number of Participants Who Experienced Any Dose-Limiting Toxicity (DLT) During First Cycle - Day 1 to 28 — 0; 0; 1; 0 Participants